Full Length ArticleSelf-assembly behavior of amphiphilic poly(ethylene glycol)-conjugated 10-Hydroxycamptothecin (cas 19685-09-7) in water and its cytotoxicity assay

Add time:09/01/2019    Source:sciencedirect.com

A PEGylated 10-Hydroxycamptothecin (cas 19685-09-7) (HCPT) conjugate, an amphiphilic prodrug, in which two hydrophobic HCPT molecules were conjugated to the two ends of a hydrophilic poly(ethylene glycol) bis(carboxymethyl) ether (PEG-biCOOH) molecule, was synthesized by esterification of the terminal carboxylic groups of PEG-biCOOH and the 10-OH groups of HCPT molecules. The obtained conjugate, denoted as PEG-bi(COO-HCPT), was characterized using NMR, MALDI-TOF MS, HPLC, elemental analyses, FT-IR, and UV–Vis spectroscopy. Especially, the surface activity and self-assembly behavior of the amphiphilic conjugate in water were examined using equilibrium surface tension and fluorescence techniques. The prodrug exhibits a high drug content of ∼52.7 wt% and the significantly enhanced water-solubility of HCPT from ∼1.41 μmol/L to ∼2.04 mmol/L. The PEG-bi(COO-HCPT) in water can self-assemble into vesicles with ∼130 nm in size at a concentration higher than ∼23 μmol/L, as evidenced using negative-staining, freeze-fracture, and cryogenic TEM, AFM, conductivity, fluorescence, and dynamic light scattering techniques. Furthermore, the cytotoxicity of the prodrug was evaluated against A549 non-small cell lung cancer (NSCLC) cells (Sensitive cells), human hepatoma (HepG2) cells (Non-sensitive cells), human umbilical vein endothelial cells (HUVEC, Normal cells), showing excellently improved cytotoxicity in comparison with pristine HCPT. This work provides a better understanding of self-assembly behavior of amphiphilic prodrugs in solutions and demonstrates that PEGylation of HCPT might be one of the promising strategies to improve its therapeutic efficacy.

We also recommend Trading Suppliers and Manufacturers of 10-Hydroxycamptothecin (cas 19685-09-7). Pls Click Website Link as below: cas 19685-09-7 suppliers

Prev:Enzyme/pH dual-responsive polymer prodrug nanoparticles based on 10-Hydroxycamptothecin (cas 19685-09-7)-carboxymethylchitosan for enhanced drug stability and anticancer efficacy
Next:ORIGINAL ARTICLEMenthol-modified casein nanoparticles loading 10-Hydroxycamptothecin (cas 19685-09-7) for glioma targeting therapy)